RT Journal Article
SR Electronic
T1 Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 255
OP 263
DO 10.7497/j.issn.2095-3941.2014.04.004
VO 11
IS 4
A1 Si-Han Wu
A1 Jun-Feng Bi
A1 Timothy Cloughesy
A1 Webster K. Cavenee
A1 Paul S. Mischel
YR 2014
UL http://www.cancerbiomed.org/content/11/4/255.abstract
AB Glioblastoma (GBM) is one of the most lethal human cancers. Genomic analyses define the molecular architecture of GBM and highlight a central function for mechanistic target of rapamycin (mTOR) signaling. mTOR kinase exists in two multi-protein complexes, namely, mTORC1 and mTORC2. These complexes differ in terms of function, regulation and rapamycin sensitivity. mTORC1 is well established as a cancer drug target, whereas the functions of mTORC2 in cancer, including GBM, remains poorly understood. This study reviews the recent findings that demonstrate a central function of mTORC2 in regulating tumor growth, metabolic reprogramming, and targeted therapy resistance in GBM, which makes mTORC2 as a critical GBM drug target.